Shree Pacetronix Limited has completed significant equity transactions involving promoter Akash Sethi, who has filed comprehensive regulatory disclosures under SEBI regulations. Following a recent warrant conversion and a substantial off-market share acquisition, the promoter's shareholding has increased substantially, triggering mandatory disclosure requirements under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Major Share Acquisition Transaction

Akash Sethi acquired 1,65,355 equity shares through an off-market transfer from Bio Pace Technology INC on March 20, 2026. This acquisition represents a significant increase in the promoter's equity holding, raising his shareholding percentage from 4.35% to 8.76% of the company's total share capital.

Official SEBI Regulatory Filing

The company submitted the official disclosure to BSE Limited on March 24, 2026, signed by Company Secretary Rupali Ahire. The filing was made pursuant to Regulation 29(2) of the SEBI (SAST) Regulations following the intimation received from promoter Akash Sethi regarding his substantial acquisition.

Detailed Shareholding Analysis

The comprehensive SEBI disclosure reveals the complete shareholding pattern before and after the acquisition. Prior to this transaction, Akash Sethi held 1,63,116 equity shares representing 4.35% of the total share capital along with 1,50,300 warrants.

Capital Structure Details

The company's current paid-up equity share capital stands at ₹3,74,97,000, consisting of 37,49,700 equity shares of ₹10 face value each. The total diluted share capital, including potential warrant conversions, amounts to ₹3,90,00,000 comprising 39,00,000 equity shares.

Regulatory Compliance

The entire transaction was conducted in full compliance with SEBI regulations, with proper documentation submitted to BSE Limited. Akash Sethi, serving as Promoter and Joint Managing Director with DIN 08176396, signed the detailed disclosure from Pithampur, Madhya Pradesh. The filing includes comprehensive breakdowns of voting rights, warrant holdings, and diluted shareholding calculations as mandated under regulatory guidelines.

Biofil Chemicals and Pharmaceuticals Ltd has announced its unaudited financial results for the third quarter ended December 31, 2025, under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were digitally signed and released on February 14, 2026.

Financial Performance Overview

The company's financial performance for Q3 FY26 showed mixed results compared to the previous year. The detailed financial metrics demonstrate the company's operational performance during the quarter.

Key Financial Metrics

The company maintained its equity share capital at Rs. 1627.38 lakhs across all reported periods. Earnings per share metrics for the quarter showed consistent performance between basic and diluted calculations.

Regulatory Compliance and Disclosure

The financial results were prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 as amended. The complete format of the unaudited financial results has been filed with stock exchanges and is available on the company's website at www.biofilgroup.net , as well as on BSE ( www.bseindia.com ) and NSE ( www.nseindia.com ) websites.

Company Information

Biofil Chemicals and Pharmaceuticals Ltd operates under CIN: L24233MP1985PLC002709 with its registered office located at B/12-B, Industrial Estate, Pologround, Indore-452015 (M.P.) India. The results were signed by Ketan Shah, Chairman & Managing Director (DIN: 08818212), and released from Indore on February 13, 2026.

The company has also provided a Quick Response (QR) code for easy access to the detailed financial results, enabling stakeholders to quickly retrieve comprehensive financial information.

Source: